Intracellular soluble α-synuclein oligomers reduce pyramidal cell excitability

Journal of Physiology

Volumn 594, Issue 10, 2016, Pages 2751-2772

  Kaufmann, Timothy J ^a   Harrison, Paul M ^b   Richardson, Magnus J E ^b   Pinheiro, Teresa J T ^a   Wall, Mark J ^a  

^a School of Life Sciences   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; MALE; MOUSE; NEOCORTEX; NERVE CELL EXCITABILITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NONHUMAN; PERIKARYON; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN SUBUNIT; PYRAMIDAL NERVE CELL; SEQUENCE HOMOLOGY; ULTRASOUND; WHOLE CELL PATCH CLAMP; ANIMAL; C57BL MOUSE; DRUG EFFECTS; HUMAN; INTRACELLULAR FLUID; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY;

ACTION POTENTIALS; ALPHA-SYNUCLEIN; ANIMALS; HUMANS; INTRACELLULAR FLUID; MALE; MICE; MICE, INBRED C57BL; ORGAN CULTURE TECHNIQUES; PYRAMIDAL CELLS;

EID: 84961815213     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP271968     Document Type: Article

References (61)

1. Badel L, Lefort S, Brette R, Petersen CCH, Gerstner W & Richardson MJE (2008). Dynamic I-V curves are reliable predictors of naturalistic pyramidal-neuron voltage traces. J Neurophysiol 99, 656-666.
2. Bartels T, Choi JG & Selkoe DJ (2011). α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-U123.
3. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM & Fernandez CO (2006). Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128, 9893-901.
4. Boeve BF (2013). Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 12, 469-482.
5. Braak H, Del Tredici K, Rub U, de Vos RAI, Steur E & Braak E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211.
6. Brown DR (2009). Metal binding to alpha-synuclein peptides and its contribution to toxicity. Biochem Biophys Res Commun 380, 377-381.
7. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C & Chiti F (2010). A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 6, 140-147.
8. Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ & Hill AF (2005). Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19, 1377-+.
9. Chaudhuri KR, Healy DG & Schapira AHV (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5, 235-245.
10. Chen QX, Stelzer A, Kay AR & Wong RKS (1990). GABAA receptor function is regulated by phosphorylation in acutely dissociated guinea pig hippocampal neurons. J Physiol 420, 207-221.
11. Choi W, Zibaee S, Jakes R, Serpell LC, Davletov B, Crowther RA & Goedert M (2004). Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett 576, 63-368.
12. Dani VS & Nelson SB (2009). Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. J Neurosci 29, 11263-11270.
13. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B & Kostka M (2007). Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27, 9220-9232.
14. Diogenes MJ, Dias RB, Rombo DM, Miranda HV, Maiolino F, Guerreiro P, Nasstrom T, Franquelim HG, Oliveira LMA, Castanho MARB, Lannfelt L, Bergstrom J, Ingelsson M, Quintas A, Sebastiao AM, Lopes LV & Outeiro TF (2012). Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 32, 11750-11762.
15. Dusa A, Kaylor J, Edridge S, Bodner N, Hong DP & Fink AL (2006). Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry 45, 2752-2760.
16. Fauvet B, Mbefo MK, Fares M-B, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E & Lashuel HA (2012). α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287, 15345-15364.
17. Feng LR, Federoff HJ, Vicini S & Maguire-Zeiss KA (2010). Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur J Neurosci 32, 10-17.
18. Fourcaud-Trocme N, Hansel D, van Vreeswijk C & Brunel N (2003). How spike generation mechanisms determine the neuronal response to fluctuating inputs. J Neurosci 23, 11628-11640.
19. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schuele B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T & Farrer MJ (2007). Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68, 916-922.
20. Guardia-Laguarta C, Area-Gomez E, Rueb C, Liu Y, Magrane J, Becker D, Voos W, Schon EA & Przedborski S (2014). α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci 34, 249-259.
21. Haass C & Selkoe DJ (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
22. Harrison PM, Badel L, Wall MJ & Richardson MJE (2015). Experimentally verified parameter sets for modelling heterogeneous neocortical pyramidal cell populations. PLoS Comput Biol 11, e1004165.
23. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM & Subramaniam V (2002). Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322, 383-393.
24. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW & Glabe CG (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
25. Kim H-Y, Cho M-K, Kumar A, Maier E, Siebenhaar C, Becker S, Fernandez CO, Lashuel HA, Benz R, Lange A & Zweckstetter M (2009). Structural properties of pore-forming oligomers of alpha-synuclein. J Am Chem Soc 131, 17482-17489.
26. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L & Riess O (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18, 106-108.
27. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T & Lansbury PT (2002). Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322, 1089-1102.
28. Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, Pieri L, Madiona K, Dürr A, Melki R, Verny C & Brice A, for the French Parkinson's Disease Genetics Study G (2013). G51D α-synuclein mutation causes a novel Parkinsonian - pyramidal syndrome. Ann Neurol 73, 459-471.
29. Lioudyno MI, Broccio M, Sokolov Y, Rasool S, Wu J, Alkire MT, Liu V, Kozak JA, Dennison PR, Glabe CG, Lösche M & Hall JE (2012). Effect of synthetic Aβ peptide oligomers and fluorinated solvents on Kv1.3 channel properties and membrane conductance. PLoS ONE 7, e35090.
30. Lorenzen N, Nielsen SB, Buell AK, Kaspersen JD, Arosio P, Vad BS, Paslawski W, Christiansen G, Valnickova-Hansen Z, Andreasen M, Enghild JJ, Pedersen JS, Dobson CM, Knowles TPJ & Otzen DE (2014). The role of stable alpha-synuclein oligomers in the molecular events underlying amyloid formation. J Am Chem Soc 136, 3859-3868.
31. Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, Dinh D, De La Rosa K, Sanchez M, Torres ER, Masliah E, Jentsch JD & Chesselet MF (2012). Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci 35, 870-882.
32. Martin ZS, Neugebauer V, Dineley KT, Kayed R, Zhang W, Reese LC & Taglialatela G (2011). α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem 120, 440-452.
33. Markram H (1997). A network of tufted layer 5 pyramidal neurons. Cereb Cortex 7, 523-533.
34. Mironov SL (2015). α-Synuclein forms non-selective cation channels and stimulates ATP-sensitive potassium channels in hippocampal neurons. J Physiol 593, 145-159.
35. Müller MLTM & Bohnen NI (2013). Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep 13, 377-377.
36. Oswald MJ, Tantirigama MLS, Sonntag I, Hughes SM & Empson RM (2013). Diversity of layer 5 projection neurons in the mouse motor cortex. Front Cell Neurosci 7, 174.
37. Pacheco CR, Morales CN, Ramírez AE, Muñoz FJ, Gallegos SS, Caviedes PA, Aguayo LG & Opazo CM (2015). Extracellular α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J Neurochem 132, 731-41.
38. Poewe W (2008). Non-motor symptoms in Parkinson's disease. Eur J Neurol 15, 14-20.
39. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, DiIorio G, Golbe LI & Nussbaum RL (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
40. Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H & Schapira AH (2013). A novel alpha-synuclein missense mutation in Parkinson's disease. Neurology 80, 1062-1064.
41. Robinson DW & Cameron WE (2000), Time-dependent changes in input resistance of rat hypoglossal motoneurons associated with whole-cell recording. J Neurophysiol 83, 3160-3164.
42. Rosenmund C & Westbrook GL (1993). Rundown of N-methyl-D-aspartate channels during whole cell recording in rat hippocampal neurons. Role of Ca2+ and ATP. J Physiol 470, 705-729.
43. Schmidt F, Levin J, Kamp F, Kretzschmar H, Giese A & Boetzel K (2012). Single-channel electrophysiology reveals a distinct and uniform pore complexformed by alpha-synuclein oligomers in lipid membranes. PLoS ONE 7, e42545.
44. Sekerli M, Del Negro CA, Lee RH & Butera RJ (2004). Estimating action potential thresholds from neuronal time-series: new metrics and evaluation of methodologies. IEEE Trans Biomed Eng 51, 1665-1672.
45. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C & Hall JE (2006). Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128, 637-647.
46. Sreerama N & Woody RW (1993). A self-consistent method for the analysis of protein secondary structure from circular-dichroism. Anal Biochem 209, 32-44.
47. Tanaka M, Collins SR, Toyama BH & Weissman JS (2006). The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585-589.
48. Tosatto L, Andrighetti AO, Plotegher N, Antonini V, Tessari I, Ricci L, Bubacco L & Dalla Serra M (2012). Alpha-synuclein pore forming activity upon membrane association. Biochim Biophys Acta Biomembranes 1818, 2876-2883.
49. Uhlenbeck GE & Ornstein LS (1930). On the theory of the Brownian motion. Phys Rev 36, 823-841.
50. van Rooijen BD, van Leijenhorst-Groener KA, Claessens MMAE & Subramaniam V (2009). Tryptophan fluorescence reveals structural features of alpha-synuclein oligomers. J Mol Biol 394, 826-833.
51. Vivacqua G, Casini A, Vaccaro R, Fornai F, Yu S & D'Este L (2011). Different sub-cellular localization of alpha-synuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies. J Chem Neuroanat 41, 97-110.
52. Volles MJ & Lansbury PT (2002). Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-602.
53. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC & Lansbury PT (2001). Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
54. Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LTT, Liao J, Auclair JR, Johnson D, Landeru A, Simorellis AK, Ju S, Cookson MR, Asturias FJ, Agar JN, Webb BN, Kang C, Ringe D, Petsko GA, Pochapsky TC & Hoang QQ (2011a). A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 108, 17797-17802.
55. Wang Y-Q, Buell AK, Wang X-Y, Welland ME, Dobson CM, Knowles TPJ & Perrett S (2011b). Relationship between prion propensity and the rates of individual molecular steps of fibril assembly. J Biol Chem 286, 12101-12107.
56. Whitmore L & Wallace BA (2004). DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 32, W668-W673.
57. Whitmore L & Wallace BA (2008). Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 89, 392-400.
58. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campionic S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH & Riek R (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108, 4194-4199.
59. Xue W-F, Hellewell AL, Hewitt EW & Radford SE (2010). Fibril fragmentation in amyloid assembly and cytotoxicity: when size matters. Prion 4, 20-25.
60. Xue W-F, Hellewell AL, Gosal WS, Homans SW, Hewitt EW & Radford SE (2009). Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem 284, 34272-34282.
61. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Tortosa EG, del Ser T, Munoz DG & de Yebenes JG (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55, 164-173.